AbCellera IPO Presentation Deck
HISTORICAL PERFORMANCE: MILESTONES
TRIPLE-DIGIT CAGR, PROFITABLE &
CASHFLOW POSITIVE¹.
Revenue USD
$0
Total Employees
2014
Closed-$900K
Seed Round
$0.9M
Milestones
2015
Secured first
discovery
partnership
contract
11
Financial statements pressed under 1. GAAP
$2.2M
2016
29
$3.5M
2017
Approved
funding for
$30M DARPA
P3 Project
Acquired
Lineage
Biosciences
Ig-Seq
Platform
$8.8M
2018
Closed $10M
Series A led
by DCVC Bio
Opened 21,000
sqft facility
$11.6M
58.4M
2019
200%
2010 03
106
Awarded
foundational
patents for
microfluidic
screening
assays for
antibodies
$25.2M
174
2020 Q3 end
Closed $105M Series A2
Approved funding for $126M
Government of Canada Project
Potential antibody therapy
for COVID-19 entered
human testing
In-licensed Alloy ATX-Gx™
Acquired OrthoMab
Bispecific Platform
Acquired Trianni Mouse"
AbCelleraView entire presentation